Registry of Lobbyists
Pfizer Canada ULC
Subject Matter: Retrospective: | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Subject Matter: Prospective: | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Categories | Description |
---|---|
Regulation | Access to Information Act & Regulations |
Legislative Proposal, Regulation | C-51 (An Act to Amend to Food and Drugs Act) Regulations |
Policy or Program | Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs |
Policy or Program | Canadian Strategy for Cancer Control |
Grant, Contribution or Other Financial Benefit | CIHR Grants |
Regulation | Clinical Trials Regulations (Division 5) |
Policy or Program | Common Drug Review Policies |
Legislative Proposal, Policy or Program | Competition Act Amendments, Competition Bureau Studies |
Policy or Program | Cross Border Trade |
Regulation | Data Protection/Patented Medicines Notice of Compliance Regulations [PM(NOC) Regulations] |
Legislative Proposal | Drug Product Review & Approval System |
Regulation | Drug Product Review & Approval System / Regulations (filing formats of drug submissions, i.e. electronic Common Technical Document (eCTD) providing review tools currently not listed in the regulations) |
Policy or Program | Federal Provincial Pharmaceutical Initiatives |
Policy or Program | Federal Tobacco Control Strategies |
Regulation | Food & Drug Regulations (Good Manufacturing Practices & Establishment Licensing) |
Regulation | Food & Drugs Act (Drug Review & Approval regulations, Amendments to FDA, Data protection, Direct-to-Consumer Advertising Regs, New Substance Notification Regulations, Clinical Registry and Disclosure Regulation) |
Legislative Proposal | Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions) |
Policy or Program | Generic Pricing Policies |
Policy or Program | Health Canada Pharmaceutical Policies and Guidelines |
Policy or Program | Health Canada Probationary / Progressive Licensing Framework |
Policy or Program | Health Canada Site Inspections' program |
Policy or Program | Health Canada Subsequent Entry Biologics Policies |
Grant, Contribution or Other Financial Benefit | Health Partners International Canada (HPIC) - Tax Credit for Pharmaceutical Donations |
Policy or Program | Improving the efficiency of the drug review and approval process (Health Canada's Blue Print/Progressive Licensing Framework) |
Policy or Program | National Pharmaceutical Strategy |
Policy or Program | Non-Insured Health Benefits (NIHB) |
Regulation | Patent Act (Patented Medicines (Notice of Compliance)) Regulations - Amendments to prices review board |
Bill or Resolution, Regulation | Patented Medicine Prices Review Board (PMPRB) Regulations |
Policy or Program | Post-Marketing Surveillance Initiatives |
Policy or Program | Science and Technology Policy |
Policy or Program | Veterans Affairs Drug Benefits Plan |
Policy or Program | Veterinary Drug Distribution (VDD) post- NOC (Notice of compliance) Manufacturing changes guidelines |
Legislative Proposal | Veterinary Drug Distribution (VDDs) Document on Antimicrobial Categorization |